An investigational PCSK9 inhibitor with a different mechanism from existing drugs in this class has been shown to safely and ...

A Verve Therapeutics treatment was found to cut cholesterol levels by more than half—with just one shot. The stock jumped ...

The results are very encouraging news for Amgen and Repatha, which is in a head-to-head marketing battle with Sanofi and Regeneron’s Praluent to be the dominant PCSK9 inhibitor. Both drugs have ...

“Although the study did not formally hypothesis-test lipoprotein(a) reduction, we did find that the drug had the characteristics we would expect in a PCSK9 inhibitor,” Koren said. “Median Lp ...

Wall Street analysts said the results for Verve’s therapy appeared competitive on efficacy, while avoiding any major safety ...

Additionally, some patients are unable to tolerate statin therapy due to adverse drug reactions (eg, myalgias, elevated liver enzymes, rhabdomyolysis). In both cases, either ezetimibe or a PCSK9 ...

In a Phase Ib trial, VERVE-102 showed it could lower bad cholesterol across doses, setting up an opt-in decision for Eli ...

VERVE-102, a drug candidate that uses a different LNP to deliver the same payload, became Verve’s lead PCSK9 program. Since then, analysts have questioned Verve about why it believes VERVE-102 ...

The drug, which currently goes by the name AZD0780, inhibits a protein called PCSK9. Merck & Co. has a competing medicine in development targeting the same protein. Merck’s drug resulted in a ...

In the global arena of biomedicine, Guangzhou's innovative drug companies are rewriting the rules with "hard‑core technology.

Merck & Co.'s peptides could be undergoing a transformation into oral tablets thanks to a $493 million licensing deal the ...